Osteoneurogen Inc.

Nanyang Technological University

Ho Sup Yoon

Han Soo Kim

Byung Soo Youn

Xuewei Liu

Ik Hwan Kim

Hui Yao

Hui Ting Toh

Sreekanth Rajan

Baik Lin Seong

Min Ju Ham

Hyeong Deok Choi

Jun Hwan Kim

Moon Kee Maeng

Co-crystals comprising the Nuclear receptor related 1 protein-ligand binding domain (Nurr1-LBD) and a cyclopentenone prostaglandin are provided. Also provided are methods of identifying or designing Nurr1-modulating ligands and compounds based on the crystal structures described herein as well as the applications of said ligands and compounds as Nurr1 modulators or medicaments.

Co-crystals of NURR1-lbd in complex with a cyclopentenone prostaglandin and modulators of NURR1

Co-crystals of Nurr1-LBD in complex with a cyclopentenone prostaglandin and modulators of Nurr1

The present invention relates to an anti-inflammatory composition, and more particularly to an anti-inflammatory composition containing, as an active ingredient, a compound represented by Formula 1 or a salt thereof, wherein the anti-inflammatory composition may inhibit inflammatory response even at an early stage by inhibiting the interaction between CD14 and LPS and blocking the expression of CD14 and the expression of TNF&#x3b1; and IL-1&#x3b2;, which are the key factors in inflammatory response, and may also regulate the expression of important factors, such as CCL2 (MCP-1), CCL7 (MCP-3), CXCL2, CHOP and NOX1, which are involved in inflammatory response.

Anti-inflammatory composition

A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity

Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity

A compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof: 

Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis

Growing community of inventors

Singapore, Singapore

Ho Sup Yoon